0001633070FALSEP.O. Box 1270LittletonMassachusetts00016330702023-03-302023-03-30UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C...
Long COVID Phase 2b/3 study may proceed under U.S. Investigational New Drug application MHRA guidance aligns on key measurements for a Long...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
Phase 2b/3 study may proceed under U.S. Investigational New Drug application Study design now accepted by U.S. and U.K. regulatory...
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange...
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using...
SCHEDULE 13G Amendment No.4 AXCELLA HEALTH INC COMMON STOCK Cusip #05454B105 Check the appropriate box to designate...
A Massachusetts-based biotech company is making waves Tuesday morning after the company reportedly received regulatory guidance from the...
By Denny Jacob Axcella Health Inc. shares surged 53% to 66 cents in after-hours trading Monday after the company said it received regulatory...
MHRA guidance aligns on key measurements for a registration trial, including primary endpoint and trial design elements IND for phase 2b/3 trial...
0001633070 false 0001633070 2022-12-30 2022-12-30 iso4217:USD xbrli:shares...
0001633070 false 0001633070 2022-12-12 2022-12-12 iso4217:USD xbrli:shares...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.